Hikma To Buy Boehringer's U.S. Injectables Business In $300 Million Deal
This article was originally published in PharmAsia News
Hikma Pharmaceuticals said Boehringer Ingelheim has agreed to sell its U.S. injectable drugs business for as much as $300 million, the Jordan-based company to pay $225 million up front.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.